menu
    • menu

    Company profile for Repare Therapeutics

    NEW Drugs in Dev: 7
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Repare Therapeutics is a leading precision oncology company enabled by our proprietary synthetic lethality approach to discovering and developing novel therapeutics. We use our genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Repare TherapeuticsCanada Flag
    Country
    Country
    Canada
    Address
    Address
    7210 Frederick-Banting, Suite 100, St-Laurent, Quebec, H4S 2A1
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.reparerx.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    euroPLX 90 Lisbon

    Not Confirmed

    envelop Contact Supplier

    euroPLX 90 Lisbon

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Repare Announces Completion of Acquisition by XenoTherapeutics
    Repare Announces Completion of Acquisition by XenoTherapeutics

    28 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260128195211/en/Repare-Announces-Completion-of-Acquisition-by-XenoTherapeutics-Inc.

    BUSINESSWIRE
    28 Jan 2026
    Share Share
    Repare Shareholders Approve Acquisition By Xenotherapeutics
    Repare Shareholders Approve Acquisition By Xenotherapeutics

    17 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260116246532/en/Repare-Shareholders-Approve-Acquisition-by-XenoTherapeutics-Inc.

    BUSINESSWIRE
    17 Jan 2026
    Share Share
    Gilead Sciences Acquires RP-3467, Pol-ATPase Inhibitor RP 3467
    Gilead Sciences Acquires RP-3467, Pol-ATPase Inhibitor RP 3467

    24 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251224800886/en/Repare-Therapeutics-Announces-Acquisition-of-Pol-ATPase-Inhibitor-RP-3467-by-Gilead-Sciences-for-Up-To-%2430-Million-in-Total-Consideration

    BUSINESSWIRE
    24 Dec 2025
    Share Share
    Repare Pharma Secures Backing From Major Shareholders
    Repare Pharma Secures Backing From Major Shareholders

    20 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251120902912/en/Repare-Therapeutics-Enters-into-Support-and-Voting-Agreements-with-Significant-Shareholders-for-Proposed-Transaction-with-XenoTherapeutics-Inc.

    BUSINESSWIRE
    20 Nov 2025
    Share Share
    Repare Nails Down Xenotherapeutics Buyout
    Repare Nails Down Xenotherapeutics Buyout

    17 Nov 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/repare-finds-fix-biotech-agrees-xenotherapeutics-buyout

    FIERCE BIOTECH
    17 Nov 2025
    Share Share
    Repare To Unveil Phase 1 LIONS Trial Data at AACR-NCI-EORTC
    Repare To Unveil Phase 1 LIONS Trial Data at AACR-NCI-EORTC

    13 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251013080571/en/Repare-Therapeutics-to-Present-Initial-Data-from-Phase-1-LIONS-Clinical-Trial-at-37th-AACR-NCI-EORTC-International-Conference-on-Molecular-Targets-and-Cancer-Therapeutics

    BUSINESSWIRE
    13 Oct 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search